Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Manual for Purchasing a Modest Jeep Wrangler for Seniors - 2From Lounge chair to Money: Online Positions That Will Change Your Profession
- 3Figure out How to Score Huge with Open Record Rewards
- 4Dear Santa: I want Botox. Why cosmetic procedures are topping holiday wish lists.
- 5Here are 10 stores where you can get a free Thanksgiving turkey
- The 12 biggest space stories of 2025 — according to you
- The Most Compelling Innovation Developments Somewhat recently
- Genesis Marks 10th Anniversary With Magma GT Concept Aimed at High-Performance Flagships
- Major railway disruptions persist as Germany braces for more snow
- Sentimental tree to shine at Arctic League annual broadcast
- Fire Allegedly Triggered by Wedding Cake Sparkler Causes Venue to Go Up in Flames, Leaving Groom with Second-Degree Burns
- Figuring out Significant Regulations and Guidelines for Organizations
- Current Chateaus: Advancement and Style
- Space station changes command, setting stage for Crew 11 departure
